Drug intelligence / Profile preview

MELCURA HoneyGel

Development stage: Unknown
Lead developer: Melcura
Administration: Topical

Overview

MELCURA HoneyGel is a medical-grade wound care product formulated with Fynbos honey, a multifloral honey sourced from South Africa's Cape biome. It is designed for the management of various wound types, including chronic non-healing ulcers (diabetic, venous, arterial, and pressure), burns, surgical wounds, and infected wounds. The gel operates through a physical mechanism of action: its high osmotic activity and low pH create a bacteriostatic environment that inhibits bacterial growth, promotes autolytic debridement of necrotic tissue, and reduces wound malodor. Enriched with vitamins C and E, it provides an optimal moist environment for natural wound healing. It is distributed by Biotech Pharmaceuticals and is classified as a medical device.

Brand names: MELCURA HoneyGelMELCURA
Other names: MELCURA HoneyGel

Beyond the preview

Go deeper on MELCURA HoneyGel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MELCURA HoneyGel.

Explore the full profile